Your browser is no longer supported. Please, upgrade your browser.
Settings
COGT Cogent Biosciences, Inc. daily Stock Chart
COGT [NASD]
Cogent Biosciences, Inc.
Index- P/E- EPS (ttm)-0.75 Insider Own0.20% Shs Outstand31.11M Perf Week8.98%
Market Cap110.71M Forward P/E- EPS next Y-0.19 Insider Trans0.00% Shs Float- Perf Month20.78%
Income-23.10M PEG- EPS next Q-0.14 Inst Own58.60% Short Float- Perf Quarter8.14%
Sales23.90M P/S4.63 EPS this Y24.70% Inst Trans179.60% Short Ratio1.41 Perf Half Y597.50%
Book/sh0.62 P/B4.50 EPS next Y56.80% ROA-52.10% Target Price4.67 Perf Year123.20%
Cash/sh- P/C- EPS next 5Y- ROE-87.80% 52W Range0.29 - 3.72 Perf YTD287.39%
Dividend- P/FCF- EPS past 5Y- ROI-101.20% 52W High-22.85% Beta-
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin- 52W Low872.88% ATR0.31
Employees72 Current Ratio2.90 Sales Q/Q-83.90% Oper. Margin-98.10% RSI (14)56.54 Volatility13.07% 12.35%
OptionableNo Debt/Eq0.00 EPS Q/Q31.10% Profit Margin-96.80% Rel Volume0.23 Prev Close2.79
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume541.96K Price2.87
Recom1.00 SMA2011.91% SMA509.54% SMA200105.93% Volume6,287 Change2.87%
Oct-14-20Initiated Ladenburg Thalmann Buy $4
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a A'bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.